Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07693660 · ClinicalTrials.gov registry record · NA
VergeRx for Smokers Not Ready to Quit
A NA study, sponsored by University of Virginia.
- Not yet
- Registry status
- NA
- Development phase
- 592
- Enrollment target
NCT07693660: Clinical Trial NA study, sponsored by University of Virginia.
NCT07693660 is a NA study that has not yet begun recruiting, run by University of Virginia. The registered enrollment target is 592 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07693660, a NA study, has not yet begun recruiting, sponsored by University of Virginia.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 592 participants
- Enrollment target
Study Summary
This study uses a factorial optimization experiment to identify which treatment components help adults who smoke and are not ready to quit in the next 30 days (smokers not ready to quit, or SNRTQ) achieve smoking cessation. Participants are recruited through Federally Qualified Health Centers (FQHCs) in Virginia and West Virginia. All participants receive at least 8 weeks of nicotine replacement therapy (NRT) patch. Using a 2×2×2×2 factorial design, the study independently tests four components: a pharmacist-delivered behavioral program (VergeRx), a text-message support program (SmokefreeTXT), the addition of an NRT lozenge to the patch, and an extended 16-week course of the NRT patch versus the standard 8 weeks. The goal is to estimate the effect of each component on biochemically confirmed smoking abstinence so that an optimized treatment package can be assembled. The primary outcome is abstinence at 26 weeks; a secondary outcome is abstinence at 52 weeks.
Primary Outcome
Point prevalence abstinence, defined as no cigarette smoking (not even a puff) within the past 7 days, biochemically confirmed using a CoVita Smokerlyzer carbon monoxide (CO) monitor at the FQHC. Participants unable to travel who report no combustible tobacco use are mailed a cotinine test completed via Zoom. Participants who do not provide outcome data are classified as smoking.
Interventions
- BEHAVIORAL SmokefreeTXT
- BEHAVIORAL VergeRx
- DRUG NRT Lozenge (Combination)
- DRUG Extended NRT Patch (16 weeks)
- DRUG Standard NRT Patch (8 weeks)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 592 participants |
| Start Date | 2027-12-01 |
| Est. Completion | 2032-11-01 |
| Phase | NA |
What is known before NCT07693660 opens enrollment
NCT07693660 is an interventional study that assigns participants to a tested intervention. The registered 592 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 5 interventions - of which SmokefreeTXT is the first listed.
NCT07693660 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07693660 about?
NCT07693660 is a clinical study titled "VergeRx for Smokers Not Ready to Quit". This study uses a factorial optimization experiment to identify which treatment components help adults who smoke and are not ready to quit in the next 30 days (smokers not ready to quit, or SNRTQ) achieve smoking cessation. Participants are recruited through Federally Qualified Health Centers (FQHCs...
What is the current status of trial NCT07693660?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 592 participants. The study started on 2027-12-01. Estimated completion is 2032-11-01.
What interventions are being tested in trial NCT07693660?
The interventions under investigation include: SmokefreeTXT (BEHAVIORAL), VergeRx (BEHAVIORAL), NRT Lozenge (Combination) (DRUG), Extended NRT Patch (16 weeks) (DRUG), Standard NRT Patch (8 weeks) (DRUG).
Who is sponsoring clinical trial NCT07693660?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07693660's enrollment target sits among peer trials
592 175th of 2000 higher than 1,826 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04701684 · 594 participants · NA
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
- NCT05491213 · 594 participants · NA
TELESCOPE- TELEhealth Shared Decision-making COaching
- NCT05867420 · 594 participants · Phase 1
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
- NCT06890884 · 594 participants · Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI